Avacopan plus rituximab offers a superior remission rate at 52 weeks and lower risk of relapse compared with prednisone taper plus rituximab, with a similar safety profile. Avacopan plus rituximab therapy for ANCA-associated vasculitis (AAV) offers superior remission rates.
/PRNewswire/ The National Kidney Foundation (NKF) and its Kidney Disease Outcomes Quality Initiative (KDOQI) are pleased to announce the publication of the.